Literature DB >> 7947228

Evaluating the response to antioestrogen toremifene treatment in DMBA induced rat mammary carcinoma.

R Huovinen1, P L Kellokumpu-Lehtinen, Y Collan.   

Abstract

Evaluation of the treatment response to hormonal therapy in experimental mammary carcinoma models usually consists of recording the changes in tumour volume or in number of tumours. We performed quantitative histology on dimethylbenz[a]anthracene(DMBA) induced rat mammary carcinoma treated with the antioestrogen toremifene. The inhibition of growth of the treated regressing tumours was not only associated with inhibition of mitosis and reduction of the neoplastic epithelium, but toremifene seemed to reduce all main tissue components. The percentual area fractions of epithelium and stroma were equal in the untreated and the treated tumours. The estimated absolute volumes of epithelium, stroma and glandular luminae as well as the mitotic index were significantly reduced during toremifene treatment in those tumours which were responding by regression to the treatment. The findings indicate growth inhibiting effect on both epithelium and stroma or on interactions between epithelium and stroma. Adding quantitative histology to the gross response analysis in experimental animal models is feasible and may elucidate the mechanisms of action of a novel hormonal treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947228      PMCID: PMC2002236     

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  31 in total

Review 1.  Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.

Authors:  L J Lerner; V C Jordan
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

2.  Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat.

Authors:  E di Salle; T Zaccheo; G Ornati
Journal:  J Steroid Biochem       Date:  1990-06-22       Impact factor: 4.292

3.  Mitotic activity, apoptosis and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with anti-estrogen toremifene.

Authors:  R Huovinen; A Wärri; Y Collan
Journal:  Int J Cancer       Date:  1993-10-21       Impact factor: 7.396

4.  The antitumor potency of progesterone antagonists is due to their differentiation potential.

Authors:  H Michna; S Gehring; W Kühnel; Y Nishino; M R Schneider
Journal:  J Steroid Biochem Mol Biol       Date:  1992-09       Impact factor: 4.292

5.  Desmoid tumours treated with triphenylethylenes.

Authors:  M D Brooks; S R Ebbs; A A Colletta; M Baum
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

6.  Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro.

Authors:  A M Wärri; R L Huovinen; A M Laine; P M Martikainen; P L Härkönen
Journal:  J Natl Cancer Inst       Date:  1993-09-01       Impact factor: 13.506

7.  Antitumour activity of folligen, a novel gonadotropin-releasing hormone analogue against DMBA-induced tumours in the rat.

Authors:  R I Nicholson; G Kéri
Journal:  Tumour Biol       Date:  1992

8.  Volume corrected mitotic index (M/V-INDEX). The standard of mitotic activity in neoplasms.

Authors:  H Haapasalo; E Pesonen; Y Collan
Journal:  Pathol Res Pract       Date:  1989-11       Impact factor: 3.250

9.  Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model.

Authors:  S P Robinson; D A Mauel; V C Jordan
Journal:  Eur J Cancer Clin Oncol       Date:  1988-12

10.  Practical stereological methods for morphometric cytology.

Authors:  E R Weibel; G S Kistler; W F Scherle
Journal:  J Cell Biol       Date:  1966-07       Impact factor: 10.539

View more
  2 in total

Review 1.  Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

2.  Oral administration of the broad-spectrum antibiofilm compound toremifene inhibits Candida albicans and Staphylococcus aureus biofilm formation in vivo.

Authors:  Kaat De Cremer; Nicolas Delattin; Katrijn De Brucker; Annelies Peeters; Soña Kucharíková; Evelien Gerits; Natalie Verstraeten; Jan Michiels; Patrick Van Dijck; Bruno P A Cammue; Karin Thevissen
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.